Rallybio (RLYB) vs Stablecoin Development (SDEV)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Rallybio (RLYB) has outperformed Stablecoin Development (SDEV) over the past year, gaining 268.7% versus a loss of 66.8%. Over five years, RLYB leads with a -86.3% price change compared with -99.9% for SDEV. Rallybio is the larger company by market cap ($90.4 million vs $79.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | RLYB | SDEV |
|---|---|---|
| Share price | $17.02 | $1.54 |
| Market cap | $90.42M | $79.70M |
| 1-day change | +0.18% | -22.61% |
| YTD return | +209.58% | -92.94% |
| 1-year return | +268.71% | -66.83% |
| 5-year return | -86.32% | -99.94% |
| P/E ratio (TTM) | 2.12 | — |
| EPS (TTM) | $8.01 | $-21.13 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.57 | $99.75 |
| 52-week low | $3.67 | $0.78 |
| Distance from 52-week high | -3.15% | -98.46% |
| Average volume | 21.33K | 11.74M |
| Shares outstanding | 5.31M | 51.75M |
| Employees | 7 | 2 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RLYB has outperformed SDEV by 335.5 percentage points over the past year.
About Rallybio
RLYB stock →Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
About Stablecoin Development
SDEV stock →Stablecoin Development Corporation engages in the accumulation and holding of digital assets for participation in blockchain-based networks. The company focuses on the accumulation, holding, and deployment of SKY, a protocol token of the decentralized Sky Protocol.
Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees
RLYB vs SDEV FAQ
Which is bigger, Rallybio or Stablecoin Development?
Rallybio (RLYB) is larger, with a market capitalization of $90.42M compared with $79.70M for Stablecoin Development (SDEV).
Which stock has performed better over the past year, RLYB or SDEV?
RLYB returned +268.71% over the past 12 months, compared with -66.83% for SDEV (price return, excluding dividends). Past performance does not predict future results.
Are Rallybio and Stablecoin Development in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.